See more : Nukkleus Inc. (NUKK) Income Statement Analysis – Financial Results
Complete financial analysis of Xspray Pharma AB (publ) (XSPRAY.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Xspray Pharma AB (publ), a leading company in the Biotechnology industry within the Healthcare sector.
- Dlaboratory Sweden AB (publ) (DLAB.ST) Income Statement Analysis – Financial Results
- Accor SA (AC.PA) Income Statement Analysis – Financial Results
- Chiu Ting Machinery Co., Ltd. (1539.TW) Income Statement Analysis – Financial Results
- Mijem Newcomm Tech Inc. (MJEM.CN) Income Statement Analysis – Financial Results
- Eli Lilly and Company (LLY.SW) Income Statement Analysis – Financial Results
Xspray Pharma AB (publ) (XSPRAY.ST)
About Xspray Pharma AB (publ)
Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 277.00K | 331.55K | 792.00K | 3.64M |
| Cost of Revenue | 9.19M | 9.53M | 8.87M | 1.41M | 4.80M | 0.00 | -4.13M | -6.19M | 5.29M |
| Gross Profit | -9.19M | -9.53M | -8.87M | -1.41M | -4.80M | 277.00K | 4.47M | 6.99M | -1.65M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 1,347.10% | 881.94% | -45.44% |
| Research & Development | 33.59M | 22.22M | 38.57M | 6.55M | 3.43M | 5.54M | 3.35M | 0.00 | 0.00 |
| General & Administrative | 0.00 | 109.60M | 58.38M | 47.10M | 42.33M | 0.00 | 8.62M | 3.77M | 4.27M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.97M | 0.00 | 0.00 | 0.00 |
| SG&A | 169.57M | 109.60M | 58.38M | 47.10M | 42.33M | 16.97M | 8.62M | 3.77M | 4.27M |
| Other Expenses | 0.00 | -438.00K | 0.00 | -5.00K | 0.00 | 414.00K | 9.14M | 7.27M | 6.16M |
| Operating Expenses | 181.73M | 131.38M | 96.95M | 53.65M | 45.76M | 22.92M | 17.76M | 11.05M | 10.44M |
| Cost & Expenses | 181.73M | 131.38M | 96.95M | 53.65M | 45.76M | 22.92M | 13.63M | 4.85M | 15.73M |
| Interest Income | 2.73M | 1.42M | 1.26M | 1.05M | 862.00K | 150.00K | 80.26K | 21.00K | 0.00 |
| Interest Expense | 675.00K | 12.00K | 4.00K | 6.00K | 69.00K | 31.00K | 881.00 | 59.00K | 3.00K |
| Depreciation & Amortization | 9.19M | 9.53M | 8.87M | 1.41M | 4.80M | 4.03M | 1.17M | 665.00K | 608.00K |
| EBITDA | -169.82M | -122.13M | -87.82M | -50.99M | -40.90M | -19.07M | -12.65M | -3.40M | -11.48M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,820.22% | -3,629.00% | -425.88% | -315.38% |
| Operating Income | -180.77M | -133.07M | -97.95M | -53.46M | -45.71M | -23.22M | -13.28M | -4.06M | -12.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,381.59% | -4,004.80% | -512.50% | -332.09% |
| Total Other Income/Expenses | 1.08M | 1.40M | 1.26M | 1.05M | -15.00K | -458.00K | -44.00K | -37.56K | -3.00K |
| Income Before Tax | -179.68M | -131.67M | -96.70M | -52.41M | -45.77M | -23.10M | -13.20M | -4.10M | -12.09M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,338.63% | -3,980.86% | -517.30% | -332.17% |
| Income Tax Expense | -17.00K | -1.40M | 4.00K | -107.00K | 66.00K | -427.00K | 98.47K | 22.00K | 2.00K |
| Net Income | -179.67M | -130.27M | -96.70M | -52.30M | -45.84M | -23.10M | -13.20M | -4.10M | -12.09M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -8,338.63% | -3,980.86% | -517.30% | -332.17% |
| EPS | -6.76 | -6.13 | -4.98 | -3.01 | -2.99 | -1.68 | -1.65 | -0.64 | -0.97 |
| EPS Diluted | -6.76 | -6.13 | -4.98 | -3.01 | -2.99 | -1.63 | -1.56 | -0.33 | -0.97 |
| Weighted Avg Shares Out | 26.58M | 21.26M | 19.41M | 17.37M | 15.35M | 13.72M | 8.02M | 6.41M | 12.47M |
| Weighted Avg Shares Out (Dil) | 26.59M | 21.26M | 19.41M | 17.37M | 15.35M | 14.18M | 8.48M | 12.47M | 12.47M |
Source: https://incomestatements.info
Category: Stock Reports